We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Value of Serum Galectin 3 in Patients with Hepatocellular Carcinoma: A Meta-Analysis.
- Authors
Zhang, L.; Chen, X.-J.; He, D.; Zhou, T.-Y.
- Abstract
Objective: To investigate the connection of Galectin 3 with hepatocellular carcinoma (HCC) risk. Methods: Publications were searched using PubMed, MEDLINE, EMBASE and the Chinese databases (including CNKI and WanFang) up to October 2015. Results: A total of four studies were included in this analysis. The pooled mean difference for HCC versus hepatitis was (1.98 (95% Cl: 1.13, 2.83, Z = 4.57, p < 0.00001)) and for HCC versus healthy person was (2.29 (95% CI: 2.09, 2.5, Z = 21.78, p < 0.00001). The serum Galectin 3 level in HCC was significantly higher than that in hepatitis and healthy person. The pooled sensitivity and specificity were 0.93 (95% CI: 0.86, 0.97) and 0.83 (95% CI: 0.74, 0.90), the pooled diagnostic odds ratio were 116.78 (95% CI: 0.13, 102122.46), the pooled positive likelihood ratio were 12.71 (95% CI: 0.12, 1374.27), and the pooled negative LR were 0.11 (95% CI: 0.00, 12.51). Conclusion: The serum Galectin 3 level in HCC is higher than that in hepatitis and healthy person. Serum Galectin 3 may be a possible biomarker for diagnosis of HCC.
- Subjects
HEPATOCELLULAR carcinoma; ODDS ratio; SENSITIVITY &; specificity (Statistics); HEPATITIS
- Publication
West Indian Medical Journal, 2024, Vol 71, Issue 1, p14
- ISSN
0043-3144
- Publication type
Article
- DOI
10.7727/wimj.2016.532